Scientific Seminar on Clinical Development Strategies for Multi-Regional Trials

Multi-regional clinical trials hold the potential for adding significant value to a new drug candidate, while differences in regulations and health care systems across regions provide both challenges and opportunities in clinical development. In order to enable Taiwanese biotech companies navigating the pitfalls and opportunities of including the US or Europe in their clinical development, TRPMA partnered with ERGOMED to hold a seminar on “Harnessing the Potential of the US and Europe in Multi-Regional Clinical Trials” on December 14, during which will be shared Regulatory, Operational and Commercial considerations for formulating an efficient strategy leveraging the full potential of the respective regions.

The US and Europe have mature clinical research environments with leading KOLs, reputable regulatory agencies, and diverse medical healthcare systems. With the right strategy in place, conducting clinical research in the US and Europe can accelerate drug development and add value with access to several of the largest pharmaceutical markets, ultimately benefiting more patients worldwide.